2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
7
Withdrawn
2
Not yet recruiting
2
Active not recruiting
2
Terminated
1
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Squamous-Cell Non-Small-Cell Lung Cancer
1
Interventions
Cyclophosphamide
390
Carboplatin
344
Gemcitabine
332
pembrolizumab
329
Cisplatin
328
Paclitaxel
297
Radiotherapy
296
Docetaxel
286
Bevacizumab
253
Rituximab
234
Capecitabine
223
Nivolumab
220
Dexamethasone
206
Fluorouracil
190
fludarabine
177
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
153
Irinotecan
148
Leucovorin
144
Etoposide
144
Cytarabine
133
Cetuximab
129
Bortezomib
129
fludarabine phosphate
128
Lenalidomide
126
Erlotinib Hydrochloride
120
Filgrastim
119
Temozolomide
113
Radiosurgery
113
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
bemarituzumab
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts